Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease

• Status: Completed
• Trial end date: 2012-09-25
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the safety, efficacy and acceptability of two new eye drop formulations compared with Refresh Tears® in patients with dry eye disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Carboxymethylcellulose Sodium; Ophthalmic Solutions; Tetrahydrozoline

Criteria

Inclusion Criteria:

• Current use of an artificial tear product at least twice daily for at least 3 months, on average

• Ability/agreement to continue wearing existing spectacle correction (glasses) during study

Exclusion Criteria:

• Anticipated contact lens wear during study or contact lens use within 6 months

• Active ocular infection or allergy

• Use of any topical ophthalmic medications (eg, topical ophthalmic steroids, glaucoma drops) within 2 weeks

• Use of any topical cyclosporine products within 3 months